top of page
Browse by category
Search


Duodenal mucosal resurfacing may prevent weight recurrence following GLP-1 discontinuation
An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining weight, according to a study, ‘Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial—midpoint cohort results’, presented at Digestive Disease Week 2026. Nearly one in five adults with obesity have taken a glucagon-like peptide-1 (GLP-1), an


ForePass replicates effects of bariatric surgery and outperforms GLP-1
The ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomised preclinical study, according to a study led by Professor Ivo Boskoski, Professor of Digestive Endoscopy at Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Rome, Lazio, Italy. ForePass endoscopic metabolic bypass platform


Metabolic surgery may reverse MASH cirrhosis
Researchers at Cleveland Clinic have demonstrated that metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis regression can occur following metabolic and bariatric surgery (MBS). The study, “Can Metabolic Surgery Regress MASH Cirrhosis? Evidence From Paired Biopsies,” was presented at the 2026 Digestive Disease Week Annual Meeting. In a retrospective cohort of patients with biopsy-proven compensated MASH cirrhosis undergoing MBS, investigators evaluated long-term


Integrating measurements captures disease risks missed by BMI alone
Researchers at Lund University and AstraZeneca have reported that integrating measurements such as body fat percentage and waist circumference captures disease risks missed by BMI alone. This study provides increasing evidence for including more parameters than BMI in the diagnosis of obesity. In recent years, research has shown that there are several limitations with BMI alone when it comes to assessing adiposity quantity, distribution, as well as the risk of developing vari


ESG associated with greater short-term weight loss than oral semaglutide
Endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity, according to the outcomes from a comparative study, ‘Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real World Comparative Study’, presented at the European Society of Gastrointestinal Endoscopy (ESGE) Days 2026. Endoscopic sleeve gastroplasty is a minimally invasive endoscopic procedure that reduces gastric


Gut microbiota play a role in metabolic health post-MBS
Changes in gut microbiota after bariatric surgery are strongly linked to altered metabolic health and sustained improvement in type 2 diabetes, according to a study led by researchers at the University of Gothenburg. Bariatric surgery is an effective treatment for obesity and type 2 diabetes, but patient outcomes vary widely. The current study, published in Nature Metabolism, suggests that the variations are partly explained by differences in how the composition of gut bacter
Browse by tag






bottom of page
